Ocriplasmin: A Welcome Option for Vitreomacular Disease

Now approved in both the United States and Europe, the proteolytic enzyme ocriplasmin brings a less invasive treatment option for vitreomacular adhesion to the table.
Medscape Ophthalmology

Full Story →